Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc
Journal website http://www.thejh.org

Case Report

Volume 9, Number 1-2, April 2020, pages 30-32


Prolonged Remission by Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin’s Lymphoma

Figure

Figure 1.
Figure 1. Serial PET scans demonstrating the relapsed Hodgkin’s lymphoma and treatment response. (a) PET scan showing disease progression with disseminated skeletal and visceral involvement after BV treatment. (b) Disease significantly controlled by anti-PD-1 treatment. (c) Multiple nodal and bony relapses following 16 months of remission. (d) Remission state regained after anti-PD-1 and BV combination treatment. PET: positron emission tomography; BV: brentuximab-vedotin; PD-1: programmed cell death protein-1.